# OS Therapies Inc: overview OSTX · NYSE · CIK 1795091 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/ostx.md) · [Financials](/companies/ostx/financials.md) · [Filings](/companies/ostx/filings.md) · [Insiders](/companies/ostx/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.18)](/filings/0001213900-25-110829.md) | not reported | [(0.18)](/filings/0001213900-26-058070.md) | [(0.19)](/filings/0001213900-26-090238.md) | [(0.21)](/filings/0001213900-25-110829.md) | not reported | [(0.27)](/filings/0001213900-26-058070.md) | [(0.20)](/filings/0001213900-26-090238.md) | | Free cash flow | $k | not reported | not reported | [(3,592)](/filings/0001213900-26-058070.md) | [(2,677) d](/filings/0001213900-26-090238.md) | [(4,706) d](/filings/0001213900-25-110829.md) | [(3,730) d](/filings/0001213900-26-036629.md) | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.46)](/filings/0001213900-25-026238.md) | [(1.28)](/filings/0001213900-26-036629.md) | [(0.98)](/filings/0001213900-26-036629.md) | | Free cash flow | $m | not reported | not reported | [(14.7)](/filings/0001213900-26-036629.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ostx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.5m | 777,651 | | Added +308,184 | | [CM Management, LLC](/funds/1841857.md) | 2026-06-30 | $760.0k | 400,000 | | Unchanged | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $573.4k | 301,794 | | Added +21,749 | | [HOWARD FINANCIAL SERVICES, LTD.](/funds/1768130.md) | 2026-06-30 | $471.2k | 248,001 | | Added +2,565 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $460.7k | 242,479 | | Added +177,707 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $330.9k | 174,132 | | Added +57,469 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $228.2k | 120,100 | | Added +28,900 | | [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $191.2k | 100,640 | | New +100,640 | | [HighTower Advisors, LLC](/funds/1462245.md) | 2026-06-30 | $162.5k | 85,550 | | Added +70,350 | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $134.6k | 70,817 | | Added +4,763 | ## Recent filings [All 243 filings](/companies/ostx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-19 | 08:47 ET | [8-K](/filings/0001213900-26-110497.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-110497 | | 2026-10-05 | 16:37 ET | [8-K](/filings/0001213900-26-106849.md) | 1.01 Entry into a material agreement; 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-106849 | | 2026-09-10 | 17:28 ET | [8-K](/filings/0001213900-26-098880.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-098880 | | 2026-09-09 | 16:17 ET | [8-K](/filings/0001213900-26-098403.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001213900-26-098403 | | 2026-08-21 | 16:50 ET | [8-K](/filings/0001213900-26-092651.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001213900-26-092651 | | 2026-08-14 | 17:01 ET | [10-Q](/filings/0001213900-26-090238.md) | Quarterly report, period 2026-06-30 | 0001213900-26-090238 | | 2026-08-12 | 16:56 ET | [8-K](/filings/0001213900-26-088435.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001213900-26-088435 | | 2026-08-06 | 16:13 ET | [8-K](/filings/0001213900-26-086150.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001213900-26-086150 | | 2026-07-29 | 17:00 ET | [8-K](/filings/0001213900-26-082876.md) | 1.02 Termination of a material agreement | 0001213900-26-082876 | | 2026-07-24 | 16:16 ET | [DEF 14A](/filings/0001213900-26-081390.md) | Proxy statement, period 2026-09-09 | 0001213900-26-081390 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-036629.md), filed Mar 31, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1795091 - Tickers: OSTX - Exchange: NYSE - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 21:01 ET. No prices; not investment advice.